PDX: Difference between revisions
CSV import |
CSV import |
||
| Line 32: | Line 32: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 21:37, 17 March 2025
PDX or Patient Derived Xenograft is a type of cancer research technique where cancerous tissue from a patient is implanted into an immunodeficient mouse for study. This method is used to create a model that closely mimics the patient's disease, allowing for personalized treatment strategies.
History[edit]
The use of PDX models in cancer research began in the 1980s. The technique was developed as a way to study the biology of human cancers in an in vivo setting. Over the years, PDX models have been used to study a variety of cancers, including breast cancer, lung cancer, colorectal cancer, and pancreatic cancer.
Methodology[edit]
The process of creating a PDX model begins with the surgical removal of a tumor from a patient. The tumor tissue is then implanted into an immunodeficient mouse, either subcutaneously or orthotopically (in the same organ from which the tumor originated). The mouse is then monitored for tumor growth. Once the tumor has grown to a sufficient size, it can be removed and further implanted into additional mice for study.
Applications[edit]
PDX models are used in a variety of research applications. They are often used in drug discovery and preclinical trials to test the efficacy of new cancer treatments. PDX models can also be used to study the biology of cancer, including tumor growth, metastasis, and response to therapy.
Limitations[edit]
While PDX models are a valuable tool in cancer research, they do have some limitations. One major limitation is that they require the use of immunodeficient mice, which do not fully represent the human immune system. This can limit the ability to study the role of the immune system in cancer progression and response to therapy. Additionally, the process of creating a PDX model can be time-consuming and expensive.
